Vita Imaging Inc.

The final countdown has begun—less than 7 days left to invest! ?? $735K+ raised, 230+ investors already on board ?? AURA? detects skin cancer in seconds—without a biopsy ?? FDA study in progress, expansion to EU & UK next ?? Patent-protected technology in a $204.8B market This round is closing—consider investing today:?https://lnkd.in/e8RA9jiW

We're incredibly grateful—over?218 investors have helped us surpass $700K!?With just?15 days left, this is your chance to join us before the round closes. Vita Imaging is advancing toward FDA clearance and preparing for U.S. market entry, with expansion plans for the EU & UK on the horizon. Haven’t invested yet? Now’s your chance:?https://lnkd.in/e8RA9jiW This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

Big news! We have launched an FDA clinical study with VA Boston & VA Tampa to validate AURA?, our non-invasive skin cancer detection device. This is a huge step forward in our mission to transform skin cancer detection. Why This Matters: ?? Top Medical Institutions: The study is led by Dr. Rebecca Hartman, Chief of Dermatology at VA Boston and Assistant Professor at Harvard Medical School. ?? Key FDA Milestone: This clinical study brings us one step closer to FDA approval and U.S. market launch. ?? Veteran Health Impact: Veterans are at increased risk for skin cancer, and AURA?’s real-time, non-invasive technology could lead to earlier detection and better outcomes. ?? Read the full press release here: https://lnkd.in/g_wrdFyk Be part of our breakthrough in skin cancer diagnostics. Invest in Vita Imaging today! https://lnkd.in/e8RA9jiW

We’ve Raised Over $500,000 – Join the Momentum! We’re thrilled to announce that Vita Imaging has raised over $500,000 on StartEngine! This milestone brings us one step closer to delivering our AURA? technology to market and transforming cancer diagnostics. Your support is driving advancements in early skin cancer detection, progress toward FDA approval, and plans for global expansion. Let’s continue this momentum—be part of a mission that’s saving lives and shaping the future of healthcare. https://lnkd.in/e8RA9jiW

The Future of Diagnostics: AURA? Goes Beyond Skin Cancer Skin cancer is just the beginning. With colorectal cancer being the second leading cause of cancer-related deaths in the U.S., there’s an urgent need for faster, more accurate diagnostics. Leveraging AURA?’s Raman spectroscopy technology, we’re exploring applications in colorectal cancer detection. Studies have demonstrated the ability to differentiate between normal and malignant tissues in just seconds. This technology has the potential to streamline diagnostics, reduce unnecessary procedures, and save lives. Join us as we advance toward a future where cancer detection is faster, safer, and smarter across multiple types of cancer Invest in the Future of Multi-Cancer Diagnostics Today https://lnkd.in/e8RA9jiW

Join Us for an Exclusive Look Into Vita Imaging’s Vision for 2025 At Vita Imaging, we’re redefining how cancer is detected. Our AURA? device offers rapid, non-invasive detection in under 2 seconds, and now we’re sharing our next steps. Join Our Investor Webinar to Learn More: ?? FDA Clinical Study with James A. Haley Veterans Hospital ?? Expansion into the U.S., EU, and Australia ?? Our plans to grow in the $204.8B cancer diagnostics market ??? Date & Time: Jan. 16, 5 PM PST ?? Register Now: https://lnkd.in/gqJ9ShSc? Be part of our journey to make early cancer detection accessible to all.

At Vita Imaging, we’re not stopping with skin cancer. AURA? is built on a versatile platform technology that can be applied to detecting other cancers, such as lung, oral, nasal, and colon. This means that once AURA? reaches the market, we will be ready to quickly develop and deploy new diagnostic devices. Our current research is already extending beyond skin cancer, and future products are set to leverage the same Raman spectroscopy technology that powers AURA?. This reduces development time and speeds up regulatory approval, ensuring faster time to market for additional life-saving tools.? ?? Your investment today supports a future where cancer detection is faster, less invasive, and more accessible across multiple medical fields. https://lnkd.in/e8RA9jiW

Check Out this Article: Early-Stage Vita Imaging’s Tech Could Transform a $200B MCED Market—Are You In? https://lnkd.in/gwJeXUJk

We’re excited to invite you to Vita Imaging’s upcoming investor webinar, where our CEO, Thinh Tran, will discuss our innovative AURA? technology, share our achievements, and reveal our future plans. Here’s your chance to dive into the science and business strategy behind our groundbreaking cancer diagnostics device. Highlights: ???Non-invasive skin cancer detection?in under two seconds ???Over 20 years of research?backing our technology ???Positioned to enter the 2032 $200B cancer diagnostics market Event Details:? ???Date:?Nov. 20th, 5 PM PST ???Join Here:? https://lnkd.in/gPyG3rjz Reserve your spot to learn how Vita Imaging is set to revolutionize cancer diagnostics!

Each year, the U.S. spends $1.6 billion on unnecessary biopsies for skin cancer. AURA? can significantly reduce this cost while providing faster, more accurate diagnoses. ?? $1.6B spent on mostly unnecessary biopsies: AURA? reduces the need for mostly unnecessary biopsies. ?? Instant results: AURA? provides skin cancer detection in under 2 seconds. ?? Non-invasive: Easier on patients and physicians, improving the diagnostic process. ?? 2025 launch: AURA? will be ready for the U.S. market once FDA approval is secured. Help us bring this efficient, life-saving device to healthcare providers. Invest today! https://lnkd.in/gApEn5Vq [This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.]